{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:40:26Z","timestamp":1793047226370,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.schres.2026.05.017","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T17:30:34Z","timestamp":1780939834000},"page":"156-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Hyperlipidemia correlated with better neurocognition in patients with schizophrenia"],"prefix":"10.1016","volume":"295","author":[{"given":"Kara B.","family":"Miecznikowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry A.","family":"Nasrallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.schres.2026.05.017_bb0005","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1089\/met.2023.0003","article-title":"Antipsychotic-Induced Metabolic Syndrome: A Review","volume":"21","author":"Akinola","year":"2023","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"10.1016\/j.schres.2026.05.017_bb0010","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.neubiorev.2021.03.028","article-title":"The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: Network meta-analyses of randomized controlled trials","volume":"126","author":"Baldez","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"6","key":"10.1016\/j.schres.2026.05.017_bb0015","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1017\/S0033291716003366","article-title":"The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis","volume":"47","author":"Bora","year":"2017","journal-title":"Psychol. Med."},{"issue":"8","key":"10.1016\/j.schres.2026.05.017_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci14080791","article-title":"Treatment of cognitive impairment associated with schizophrenia spectrum disorders: new evidence, challenges, and future perspectives","volume":"14","author":"Calzavara-Pinton","year":"2024","journal-title":"Brain Sci."},{"issue":"2","key":"10.1016\/j.schres.2026.05.017_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13020320","article-title":"Impact of physical exercise alone or in combination with cognitive remediation on cognitive functions in people with schizophrenia: a qualitative critical review","volume":"13","author":"Deste","year":"2023","journal-title":"Brain Sci."},{"issue":"2","key":"10.1016\/j.schres.2026.05.017_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23020786","article-title":"Metabolic syndrome: updates on pathophysiology and management in 2021","volume":"23","author":"Fahed","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.schres.2026.05.017_bb0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jamapsychiatry.2024.2890","article-title":"Antipsychotic Drugs and Cognitive Function: A Systematic Review and Network Meta-Analysis","volume":"82","author":"Feber","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"13","key":"10.1016\/j.schres.2026.05.017_bb0040","doi-asserted-by":"crossref","first-page":"7092","DOI":"10.3390\/ijms23137092","article-title":"Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction","volume":"23","author":"Goh","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.schres.2026.05.017_bb0045","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae412","article-title":"Cerebral white matter myelination is associated with longitudinal changes in processing speed across the adult lifespan","volume":"6","author":"Gong","year":"2024","journal-title":"Brain Commun."},{"issue":"5","key":"10.1016\/j.schres.2026.05.017_bb0050","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1001\/jamapsychiatry.2021.0015","article-title":"Association Between Cardiovascular Risk Factors and Cognitive Impairment in People With Schizophrenia: A Systematic Review and Meta-analysis","volume":"78","author":"Hagi","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.05.017_bb0055","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev-pharmtox-051921-093250","article-title":"Cognitive Impairment Associated with Schizophrenia: From Pathophysiology to Treatment","volume":"63","author":"Javitt","year":"2023","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"1","key":"10.1016\/j.schres.2026.05.017_bb0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/oxfordjournals.schbul.a006990","article-title":"Neurocognitive Assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project Schizophrenia Trial: Development, Methodology, and Rationale","volume":"29","author":"Keefe","year":"2003","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2026.05.017_bb0065","doi-asserted-by":"crossref","DOI":"10.1136\/gpsych-2022-100823","article-title":"A glimpse of gender differences in schizophrenia","volume":"35","author":"Li","year":"2022","journal-title":"Gen. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2026.05.017_bb0070","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/s41380-023-01949-9","article-title":"Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment","volume":"28","author":"McCutcheon","year":"2023","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2026.05.017_bb0075","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/schbul\/sbae051","article-title":"Measuring Cognitive Impairments Associated With Schizophrenia in Clinical Practice: Overview of Current Challenges and Future Opportunities","volume":"51","author":"Nuechterlein","year":"2025","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2026.05.017_bb0080","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3390\/cells9040812","article-title":"Myelin Fat Facts: An Overview of Lipids and Fatty Acid Metabolism","volume":"9","author":"Poitelon","year":"2020","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.schres.2026.05.017_bb0085","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2337\/dc24-0537","article-title":"Association of Metabolic Syndrome With Neuroimaging and Cognitive Outcomes in the UK Biobank","volume":"47","author":"Qureshi","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.schres.2026.05.017_bb0090","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.schres.2024.09.008","article-title":"Insulin-resistance as a modifiable pathway to cognitive dysfunction in schizophrenia: A systematic review","volume":"274","author":"Salvi","year":"2024","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2026.05.017_bb0095","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3390\/metabo15030176","article-title":"Metabolic Syndrome and Schizophrenia: Adding a Piece to the Interplay Between the Kynurenine Pathway and Inflammation","volume":"15","author":"Sapienza","year":"2025","journal-title":"Metabolites"},{"key":"10.1016\/j.schres.2026.05.017_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2022.114656","article-title":"Aerobic exercise and cognitive functioning in schizophrenia: An updated systematic review and meta-analysis","volume":"314","author":"Shimada","year":"2022","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2026.05.017_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.564240","article-title":"Cardiometabolic Risk in First Episode Psychosis Patients","volume":"11","author":"Smith","year":"2020","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.schres.2026.05.017_bb0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","article-title":"The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development","volume":"29","author":"Stroup","year":"2003","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2026.05.017_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2023.11.015","article-title":"The schizophrenia syndrome, circa 2024: What we know and how that informs its nature","volume":"264","author":"Tandon","year":"2024","journal-title":"Schizophr. Res."},{"issue":"24","key":"10.1016\/j.schres.2026.05.017_bb9000","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1001\/jama.284.24.3157","article-title":"Diurnal Variation in Fasting Plasma Glucose: Implications for Diagnosis of Diabetes in Patients Examined in the Afternoon","volume":"284","author":"Troisi","year":"2000","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.schres.2026.05.017_bb0120","doi-asserted-by":"crossref","DOI":"10.1093\/schizbullopen\/sgae013","article-title":"Pharmacological treatment of cognitive impairment associated with Schizophrenia: State of the art and future perspectives","volume":"5","author":"Vita","year":"2024","journal-title":"Schizophr. Bull. Open"},{"issue":"1","key":"10.1016\/j.schres.2026.05.017_bb0125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12991-023-00455-0","article-title":"Gender differences in prevalence and associated factors of metabolic syndrome in first-treatment and drug-na\u00efve schizophrenia patients","volume":"22","author":"Zeng","year":"2023","journal-title":"Ann. General Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.05.017_bb0130","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-024-06054-x","article-title":"Exploring the relationship between lipid metabolism and cognition in individuals living with stable-phase Schizophrenia: a small cross-sectional study using Olink proteomics analysis","volume":"24","author":"Zheng","year":"2024","journal-title":"BMC Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426001714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426001714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:08:09Z","timestamp":1793045289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996426001714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"alternative-id":["S0920996426001714"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2026.05.017","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperlipidemia correlated with better neurocognition in patients with schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2026.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}